Basic Lanoxin Information

• INN (International Nonproprietary Name): Digoxin
• Brand Names Available In United Kingdom: Lanoxin, Digoxin tablets
• ATC Code: C01AA05
• Forms & Dosages: Tablets 0.0625 mg, 0.125 mg, 0.25 mg; oral elixir 0.05 mg/mL; injection ampoules 0.25 mg/mL (2 mL).
• Manufacturers In United Kingdom: GlaxoSmithKline (Lanoxin) and multiple generic suppliers such as Mylan, Amneal, Teva and Sanofi.
• Registration Status In United Kingdom: Licensed by the MHRA for Lanoxin and generic digoxin products.
• OTC / Rx Classification: Prescription-only (Rx) in all major markets.

Key Findings From Recent Trials

Major 2022–2025 Studies

Worried that digoxin is outdated or unsafe in modern heart‑failure care?

The foundational DIG trial (1997) remains the strongest randomised controlled trial evidence and is still central to clinical reasoning about digoxin.

That trial showed digoxin (Lanoxin) reduced hospital admissions for heart failure but did not show a clear mortality benefit.

More recent work from 2022 to 2025 has focused on observational cohorts and meta‑analyses rather than new large RCTs.

Those cohort analyses show a persistent association between higher serum digoxin concentrations and worse outcomes in many observational datasets.

Conversely, studies report that low therapeutic serum levels, commonly cited as 0.5–0.9 ng/mL, correlate with symptom control and fewer admissions.

Because many recent studies are observational, causality is more difficult to prove than in the DIG trial.

Regulators and clinicians therefore balance the older RCT evidence with newer digoxin safety signal data when recommending use.

Main Outcomes

Does digoxin help patients avoid hospital?

Randomised data show a reduction in hospitalisation for symptomatic heart failure but a neutral effect on mortality.

Observational data suggest that when serum concentrations are kept low, symptomatic benefit and fewer admissions are more likely.

Safety Observations

Is digoxin risky?

Safety concerns centre on toxicity at higher serum levels, potential drug interactions and accumulation in renal impairment.

UK practice aligns with MHRA guidance supporting licensed uses with close monitoring and dose adjustment for reduced renal function.

NHS practice commonly includes routine digoxin‑level checks and electrolyte monitoring for patients on lanoxin.

Clinical Mechanism Of Action

Layman’s Explanation

How does lanoxin help the heart in plain terms?

Digoxin increases the strength of heart contractions, which can improve symptoms in some patients with heart failure.

Digoxin also slows conduction through the atrioventricular node, helping to control ventricular rate in atrial fibrillation.

Scientific Breakdown

What happens at the cellular level with digoxin?

Digoxin inhibits the Na+/K+‑ATPase pump on cardiomyocyte membranes.

That inhibition raises intracellular sodium, which secondarily increases intracellular calcium via the Na+/Ca2+ exchanger.

The higher intracellular calcium enhances myocardial contractility, producing positive inotropy.

Electrophysiological Effects

Can digoxin affect heart rhythm?

The drug has a vagomimetic effect at the AV node, which reduces ventricular rate in atrial fibrillation.

Proarrhythmic risk exists when serum levels are high or when there are electrolyte disturbances such as hypokalaemia.

Pharmacokinetics (Practical Points)

What formulations and clearance features matter to patients?

INN is digoxin and common brand Lanoxin appears across markets.

Oral tablets are available in 0.0625–0.25 mg strengths, with an oral elixir 0.05 mg/mL and injectable 0.25 mg/mL ampoules for hospital use.

Renal clearance is the main elimination pathway, so dose reduction is required in renal impairment and in many elderly patients.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Can lanoxin be prescribed for children?

Digoxin is licensed for heart failure in adults and children aged five years and older.

Digoxin is also licensed for atrial fibrillation rate control in adults.

Products in the UK include Lanoxin and generic digoxin tablets plus an oral elixir formulation.

All forms are prescription‑only and are distributed under MHRA‑licenced labelling.

Notable Off‑Label Trends

When do clinicians use digoxin off‑label?

Off‑label use is uncommon but may occur for symptomatic control in select congenital heart disease or in paediatric dosing adjustments under specialist supervision.

Clinicians increasingly reserve digoxin for patients when beta‑blockers or calcium‑channel blockers are insufficient or contraindicated.

Many NHS trusts require baseline renal function, ECG and serum electrolytes before starting and regular monitoring thereafter.

Dosage Strategy

General Dosing

What is a typical adult dose for lanoxin?

Typical adult maintenance dosing is 0.125–0.25 mg once daily, individualised by weight, renal function and interacting drugs.

Available tablet strengths are 0.0625 mg, 0.125 mg and 0.25 mg, with an oral solution of 0.05 mg/mL and injections at 0.25 mg/mL.

Condition‑Specific Dosing

How is dosing different for heart failure versus AF?

For heart failure and atrial fibrillation, clinicians commonly start low, often 0.125 mg daily for elderly or renally impaired patients.

Titration is guided by clinical response and trough serum digoxin concentrations.

Paediatric And Renal Guidance

How do children and patients with kidney disease get dosed?

Children typically receive 5–10 mcg/kg/day orally, using the paediatric solution or carefully divided tablets; a loading dose is sometimes used in specific settings.

Renal impairment requires substantial maintenance dose reductions and more frequent serum monitoring to avoid accumulation.

Elderly patients generally start at lower doses because of reduced renal clearance.

UK NHS protocols commonly aim for trough digoxin levels between 0.5–0.9 ng/mL where possible.

Safety Protocols

Contraindications

When is digoxin absolutely inappropriate?

Absolute contraindications include ventricular fibrillation, known hypersensitivity to digitalis, acute myocarditis and severe AV block or sick sinus syndrome without a pacemaker.

Relative contraindications where caution is required include electrolyte disturbances, renal impairment, thyroid disease and recent myocardial infarction.

Adverse Effects

What signs suggest lanoxin is causing problems?

Common adverse effects include nausea, vomiting, diarrhoea, dizziness, headache, weakness and visual disturbances such as yellow or blurred vision and halos.

Cardiac manifestations such as bradyarrhythmias or tachyarrhythmias may indicate toxicity and need urgent review.

Monitoring Protocols (UK):

• Baseline ECG, renal function and electrolytes prior to initiation.
• Measure serum digoxin level at steady state or if toxicity is suspected.
• Increase monitoring frequency in renal impairment, the elderly or when interacting drugs are introduced.

Overdose is life‑threatening and emergency care is required; severe cases may be treated with digoxin‑specific Fab fragments as advised by NHS guidance.

Interaction Mapping

Food Interactions

Can what I eat change how lanoxin works?

High‑fibre meals and certain herbal supplements such as St John’s wort can affect absorption and plasma concentrations.

Dietary patterns that alter electrolytes indirectly affect digoxin safety, particularly when diuretics are used.

Drug Combinations To Avoid

Which drugs raise or lower digoxin levels?

Drugs that increase digoxin exposure include amiodarone, verapamil, diltiazem, clarithromycin, erythromycin and some azole antifungals.

Potent P‑glycoprotein inhibitors will raise digoxin levels, while potent inducers such as rifampicin or some antiepileptics may reduce levels.

Diuretics that alter potassium and magnesium increase the risk of digoxin‑related arrhythmias.

Practical UK Note: Always reconcile medications on NHS e‑prescribing and consider dose reduction and extra level monitoring when starting or stopping interacting drugs.

Patient Experience Analysis

Survey Data

Do patients feel better on digoxin?

Surveys in heart failure and AF populations show mixed satisfaction, with many patients reporting reduced palpitations and improved exertional tolerance when doses are optimised.

Common concerns include frequent monitoring, side‑effects and anxiety about toxicity, which can affect adherence.

Adherence problems increase with polypharmacy and complex dosing in elderly patients.

Forum Trends

What do patients ask online about lanoxin?

Forum posts commonly describe visual disturbances, gastrointestinal upset and confusion and often ask whether these are signs of toxicity.

Many UK patients rely on GP or NHS communication for blood tests; delays or unclear follow‑up for digoxin assays can increase patient worry.

Clear patient education on toxicity signs, missed‑dose advice and the need for renal and serum monitoring is associated with better outcomes and adherence.

Distribution & Pricing Landscape

Is lanoxin hard to find and how much will it cost?

Lanoxin (GlaxoSmithKline) and multiple generic manufacturers such as Mylan, Amneal, Teva and Sanofi supply digoxin in the UK market.

Packaging generally mirrors global strengths with tablets in 0.0625, 0.125 and 0.25 mg strengths and oral elixir bottles.

Injectable ampoules (0.25 mg/mL) are usually held for inpatient use and hospital formularies.

As a generic, digoxin is inexpensive and NHS prescriptions typically favour generic digoxin unless a brand is specifically required.

Supply shortages can occur occasionally, at which point hospital protocols permit substitution between licensed products.

Storage is at room temperature and pharmacies follow standard ambient transport considerations.

Alternative Options

Comparison Table

What are alternatives to lanoxin for symptom or rate control?

Alternatives include beta‑blockers such as bisoprolol and metoprolol, calcium‑channel blockers like diltiazem and verapamil for rate control, amiodarone for rhythm control and other inotropes in advanced heart failure.

Pros And Cons

How does digoxin compare with its competitors?

Digoxin advantages include oral and intravenous routes, symptom relief in selected heart‑failure patients and AV nodal slowing for AF rate control.

Drawbacks include a narrow therapeutic index, primarily renal clearance and numerous drug interactions.

Digitoxin offers hepatic clearance and a longer half‑life but carries a risk of prolonged toxicity and is less commonly used in the UK.

Beta‑blockers provide mortality benefit in heart failure and are first‑line where tolerated, while amiodarone is potent but has systemic toxicities requiring monitoring.

Choice should be individualised by cardiology teams within NHS pathways, with digoxin often reserved when first‑line agents are unsuitable or as an adjunct.

Regulatory Status

Is lanoxin approved and what does the label say?

Digoxin carries ATC code C01AA05 and is classified as a cardiac glycoside and Group V antiarrhythmic.

In the UK, Lanoxin and generic digoxin are MHRA‑licensed and prescription‑only.

The FDA and EMA have also approved oral and injectable formulations with national labelling variations for paediatrics and packaging.

Product information emphasises the narrow therapeutic index, need for renal dosing, monitoring requirements and contraindications such as ventricular fibrillation and severe AV block unless paced.

Clinicians are encouraged to report adverse reactions to the MHRA Yellow Card scheme as part of post‑market surveillance.

Consolidated FAQ

Can I Stop Lanoxin If I Feel Better?

No.

Stop only under clinician advice as abrupt cessation may worsen control of atrial fibrillation or heart‑failure symptoms.

How Often Are Blood Levels Needed?

Baseline renal function and electrolytes are required before starting.

Measure digoxin levels once at steady state, on suspected toxicity or more frequently when renal function or interacting drugs change.

What If I Miss A Dose?

Take the missed dose as soon as you remember unless it is close to the next scheduled dose.

Do not double up doses.

When Is Digoxin Unsafe?

Digoxin is unsafe in ventricular fibrillation, acute myocarditis, severe AV block without a pacemaker and with uncontrolled electrolyte disturbances.

All advice aligns with licensed UK guidance and NHS practice.

Visual Guide

Key Visual Elements For Patient Education

What should a patient leaflet show at a glance?

Include pill images for 0.0625 mg, 0.125 mg and 0.25 mg tablets and photos of blister packs versus bottles.

Show the oral elixir concentration (0.05 mg/mL) and injectable ampoules (0.25 mg/mL) clearly for hospital use.

Infographic Suggestions (For NHS Leaflets)

Which charts help patients most?

Use a dosing ladder with paediatric weight bands and adult starting doses, plus a simple renal adjustment chart.

Include a clear signs‑of‑toxicity panel (GI symptoms, visual changes, palpitations) and an interaction map of common medications to avoid.

Add storage icons showing room temperature (20–25°C) and keep away from children, together with local NHS contact points for blood tests.

Storage & Transport

How should lanoxin be stored and moved?

Store tablets and ampoules at room temperature, typically 20–25°C, and protect from humidity and extreme heat.

Keep all forms out of reach of children and follow label guidance for the oral elixir.

Pharmacies and hospitals should use standard ambient transport and avoid prolonged exposure to high heat or freezing during delivery.

For international shipments, labelling may vary by brand name but supply must be accompanied by appropriate regulatory paperwork.

Dispose of unused or expired lanoxin via NHS pharmacy take‑back schemes; do not flush.

Guidelines For Proper Use

How should prescribers approach starting lanoxin safely?

Prescribe digoxin after a clear assessment of indication, renal function, electrolytes and baseline ECG.

Start low for elderly and renally impaired patients and adjust dose by weight, clinical response and trough serum concentrations.

Educate patients on toxicity signs and advise on missed doses, emphasising not to double up.

Monitoring Schedule (UK‑Adapted)

What monitoring is typically required under NHS protocols?

Baseline tests should include renal function, electrolytes and ECG.

Obtain a digoxin level at steady state and whenever renal function or interacting medications change.

Electrolytes should be checked at frequency determined by local NHS protocol, with closer observation for those on diuretics.

Long‑term reviews should assess ongoing need for digoxin given comorbidities and alternative therapies.

Document counselling, monitoring plans and report adverse reactions via the Yellow Card scheme as part of clinical governance.

Delivery Across United Kingdom

How can patients obtain lanoxin through an online pharmacy?

In our online pharmacy, lanoxin is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Please note that clinical guidance and MHRA licensing classify digoxin as prescription-only, and patients should follow clinician advice before starting any treatment.

Final Notes For Patients And Clinicians

What are the takeaways for someone considering lanoxin?

Lanoxin (digoxin) remains a licensed option for symptomatic heart failure and atrial fibrillation rate control in the UK when used with careful monitoring.

Its place in therapy is supported by the DIG trial showing fewer hospital admissions but no mortality benefit, with modern observational data underlining the importance of keeping serum levels low.

Safe use requires baseline renal and electrolyte assessment, regular monitoring of trough serum digoxin concentrations and vigilance for drug interactions.

Discuss alternatives such as beta‑blockers, calcium‑channel blockers or amiodarone with a cardiologist where appropriate.

Report any suspected adverse reactions via the MHRA Yellow Card scheme and ensure all prescriptions and monitoring are documented in NHS records.